Department of Clinical Medicine, University of Tromso, Norway.
Department of Clinical Medicine, University of Tromso, Norway; Department of Oncology, University Hospital of North Norway, Tromso, Norway.
Lung Cancer. 2014 Feb;83(2):272-8. doi: 10.1016/j.lungcan.2013.11.005. Epub 2013 Nov 14.
miR-210 is an important regulator of the cellular response to hypoxia. Therefore, we aimed to explore the prognostic significance of miR-210 in non-small cell lung cancer (NSCLC) patients with stage I-IIIA disease.
In addition to clinicopathological and demograpic information, tumor tissues were collected and tissue micro arrays (TMAs) were constructed from 335 patients with stage I-IIIA NSCLC. Expression of miR-210 in cancer cells and stromal cells of the tumor was assessed by in situ hybridization.
In univariate analyses, high cancer cell (p=0.039) and high stromal cell expression (p=0.008) of miR-210 were both significantly associated with an improved disease-spesific survival (DSS). High co-expression of miR-210 in cancer and stromal cells was also a positive prognostic factor for DSS (p=0.010). In multivariate analysis, miR-210 in stromal cells (p=0.011), and miR-210 co-expressed in cancer and stromal cells was an independent prognosticator for DSS (p=0.011).
We show that miR-210 in stromal cells, and co-expressed in cancer cells and stromal cells mediates an independent prognostic impact. It is a candidate marker for prognostic stratification in NSCLC.
miR-210 是细胞对缺氧反应的重要调节因子。因此,我们旨在探讨 miR-210 在 I 期至 IIIA 期非小细胞肺癌(NSCLC)患者中的预后意义。
除了临床病理和人口统计学信息外,还从 335 例 I 期至 IIIA 期 NSCLC 患者中收集肿瘤组织并构建组织微阵列(TMA)。通过原位杂交评估 miR-210 在癌细胞和肿瘤基质细胞中的表达。
在单因素分析中,高癌细胞(p=0.039)和高基质细胞表达(p=0.008)miR-210 均与改善的疾病特异性生存(DSS)显著相关。miR-210 在癌细胞和基质细胞中的高共表达也是 DSS 的阳性预后因素(p=0.010)。在多因素分析中,基质细胞中的 miR-210(p=0.011)和癌细胞与基质细胞中共表达的 miR-210 是 DSS 的独立预后因素(p=0.011)。
我们表明,基质细胞中的 miR-210 以及癌细胞和基质细胞中的共表达可独立介导预后影响。它是非小细胞肺癌预后分层的候选标志物。